Skip to content
★ Sign in to follow
TE

Theragen Etex Co.,Ltd. Stock: price and insider trades · South Korea

테라젠이텍스

KR·Mcap ₩73BHealth Care

No insider purchase over the last 90 days. The latest, by 고재훈, was filed 19 Mar 2026.

Theragen Etex Co.,Ltd.: what insiders have been doing

Theragen Etex Co.,Ltd. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). 3 insiders have disclosed 3 filings since 1 November 2025.

Open-market activity splits into 1 purchase and 1 sale; 1 insider sit on the buying side and 1 insider on the selling side. No amount is published for 2 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.

The last insider purchase was made public on 19 March 2026, 236 days ago.

Compared with its exchange (2,655 companies, median 7 filings), a count of 3 filings is below the norm. Since 2021, the database holds 3 purchases and 1 sale by insiders of the company.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
13
Thresholds
n/a
Buy Volume
€36M
3 ops. · all time
Sell Volume
€31,697
1 ops. · all time

Who traded when

BuySale
고재훈1 buy
박시홍1 sale

Since the insiders bought

  • Filed 19 Mar 2026 · 236 days ago · €314k
    -25.3%
    Entry ₩2,650 · Close 30 Oct 2026 ₩1,980

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 3,073 of 26,911 companies
72.9
score / 100
Value
87
Quality
59
FCF yld8.1%
Earn yld15%
EV/EBITDA4.3x
ROE·
Gross mgn52%
Net mgn3.9%
Debt/EBITDA1.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩1,990
Analyst consensus
·
Income statement
Revenue₩271.6B
Gross profit₩141B52% margin
EBITDA₩26.3B10% margin
Net income₩10.6B3.9% margin
Balance sheet & cash
Market cap₩73B
Total debt₩41.6B
Free Cash Flow₩5.8B
Last declaration on 19 March 2026
Declarations15 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ▲
    Executives
    €314kest.0DART
    178,602 sharesKRXDART:20260319001209
    Canonical exit: 14 Jun 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    대표이사Executives(filed)
    €32kest.0DART
    19,845 sharesShareKRXDART:20260119000251
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Executives(filed)
    €17.7Mest.0DART
    5,210,214 sharesKRXDART:20221223000090
    Canonical exit: 23 Mar 2023 (T+90)
  • ▲
    Executives(filed)
    €17.8Mest.0DART
    5,210,214 sharesKRXDART:20221222000499
    Canonical exit: 22 Mar 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    -Executives(filed)
    0DART
    ShareKRXDART:20210402002418
  • ●
    Executives
    Executives(filed)
    0DART

15 of 15 declarations

About Theragen Etex Co.,Ltd.

Teragen Etex is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions in the biotechnology field.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations